相关实验视频

Updated: Jul 14, 2026

Methyl-binding DNA capture Sequencing for Patient Tissues

Methyl-binding DNA capture Sequencing for Patient Tissues

Published on: October 31, 2016

对HER2阳性乳腺癌中新辅助药疗效相关的甲基化特征的分析

Zibai Guo¹, Jinhong Wei¹, Anping Gui¹

¹Breast Center Zone One, Zhongshan City People's Hospital, Zhongshan, China.

Frontiers in oncology

|August 22, 2025

概括

在HER2阳性乳腺癌中,DNA甲基化变化会影响治疗反应. 关键基因的甲基化模式的改变可能表明对新辅助疗法的耐药性,为治疗策略提供了潜在的新标记.

科学领域:

癌症学
表观遗传学
基因组学

背景情况:

针对HER2阳性乳腺癌的基于trastuzumab的新辅助治疗反应复杂.
在这种情况下,表观遗传因素,特别是DNA甲基化,是研究不足的.
了解这些表观遗传变化对于改善治疗结果至关重要.

研究的目的:

研究HER2阳性乳腺癌中DNA甲基化模式与新辅助疗法的反应之间的联系.
识别与治疗耐药性相关的表观遗传标记.
探索治疗抗性的潜在机制.

主要方法:

在20名HER2阳性乳腺癌患者的28个瘤样本上进行了全基因组甲基化测序.
样本包括完整反应 (pCR) 和不完整反应 (非pCR) 的患者的治疗前和治疗后样本.
在治疗前和治疗后对不同组和非pCR患者的甲基化差异进行比较分析.

主要成果:

非pCR组的治疗前瘤呈现出比pCR组更多的低甲基化.
在治疗后,非pCR瘤的甲基化增加,特别是在与免疫相关的途径中.
癌基因 (MOS,RET) 和候选基因 (KIT,LAD1,FAM110C,DAPP1) 的改变甲基化与耐药性有关.

结论:

在HER2阳性乳腺癌中,DNA甲基化变化对治疗反应和耐药性起着重要作用.
已识别的表观遗传标记可能有助于预测或克服治疗耐药性.
这些发现表明改善新辅助治疗疗效的新疗法目标.

关键词:

DNA 甲基化有HER2阳性的乳腺癌新辅助疗法全基因组甲基化序列

更多相关视频

Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer

Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer

Published on: September 18, 2020

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...